Skip to main content
Have a personal or library account? Click to login
Dopamine Agonist in Treatment of ADHD with Restless Legs Syndrome and ODD Cover

Dopamine Agonist in Treatment of ADHD with Restless Legs Syndrome and ODD

Open Access
|May 2005

Full Article

A 6-year-old male with attention deficit hyperactivity disorder who responded poorly to methylphenidate (MPH) was benefited following treatment with the dopamine agonist ropinirole, in a report from the Hopital Robert Debre, Paris, France. Restless legs syndrome and sleep problems were comorbid disorders that were linked to iron deficiency (serum ferritin 10 mcg/L) and partially relieved by a 3-month course of ferrous sulfate. Symptoms of ADHD and oppositional behavior were also improved initially but later relapsed, despite a normal ferritin level (73 mcg/L) and an increased dose of MPH. Ropinirole (0.25 to 0.5 mg, 90 min before bedtime) resulted in improvements in sleeping habits, ADHD and ODD, control of restless leg movements, and a reduction in the dose of MPH. No adverse effects were observed. [1]

COMMENT. Having failed to diagnose restless legs syndrome in my patients with ADHD, despite polysomnograms in many, I was surprised to read the authors’ reference to an incidence of up to 40%. The potential benefit of a dopamine agonist in the treatment of ADHD unresponsive to MPH is of interest and warrants further study.

Language: English
Page range: 36 - 36
Published on: May 1, 2005
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services

© 2005 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.